Kirtland Hills Capital Management LLC Raises Holdings in Danaher Co. (NYSE:DHR)

Kirtland Hills Capital Management LLC increased its stake in shares of Danaher Co. (NYSE:DHR) by 0.8% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 7,254 shares of the conglomerate’s stock after purchasing an additional 58 shares during the quarter. Danaher makes up 0.9% of Kirtland Hills Capital Management LLC’s holdings, making the stock its 23rd largest position. Kirtland Hills Capital Management LLC’s holdings in Danaher were worth $2,017,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently modified their holdings of the company. MQS Management LLC acquired a new stake in shares of Danaher in the 1st quarter worth $230,000. Crewe Advisors LLC purchased a new stake in Danaher during the 1st quarter worth approximately $162,000. Payden & Rygel Investment Group acquired a new stake in shares of Danaher during the first quarter worth $250,000. Delap Wealth Advisory LLC purchased a new stake in shares of Danaher during the first quarter valued at $348,000. Finally, CreativeOne Wealth LLC acquired a new position in shares of Danaher in the 1st quarter valued at $250,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Insider Buying and Selling at Danaher

In related news, SVP Georgeann Couchara sold 952 shares of Danaher stock in a transaction on Monday, August 26th. The shares were sold at an average price of $268.37, for a total transaction of $255,488.24. Following the sale, the senior vice president now directly owns 4,212 shares in the company, valued at $1,130,374.44. This trade represents a 18.44 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 10.90% of the stock is owned by insiders.

Danaher Price Performance

NYSE:DHR opened at $230.76 on Wednesday. The company has a market capitalization of $166.67 billion, a P/E ratio of 44.04, a P/E/G ratio of 4.24 and a beta of 0.85. The company has a quick ratio of 1.01, a current ratio of 1.37 and a debt-to-equity ratio of 0.32. Danaher Co. has a 52 week low of $207.63 and a 52 week high of $281.70. The stock’s fifty day moving average is $260.45 and its two-hundred day moving average is $260.32.

Danaher (NYSE:DHR) last announced its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share for the quarter, topping the consensus estimate of $1.57 by $0.14. Danaher had a net margin of 16.39% and a return on equity of 10.62%. The firm had revenue of $5.80 billion for the quarter, compared to the consensus estimate of $5.59 billion. During the same period in the prior year, the firm earned $2.02 EPS. The firm’s revenue for the quarter was up 3.1% on a year-over-year basis. Equities analysts expect that Danaher Co. will post 7.51 EPS for the current year.

Danaher Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, October 25th. Investors of record on Friday, September 27th were issued a $0.27 dividend. This represents a $1.08 annualized dividend and a yield of 0.47%. The ex-dividend date of this dividend was Friday, September 27th. Danaher’s dividend payout ratio (DPR) is presently 20.61%.

Analyst Upgrades and Downgrades

DHR has been the topic of several research analyst reports. Bank of America boosted their price target on Danaher from $270.00 to $275.00 and gave the company a “neutral” rating in a research note on Wednesday, July 24th. UBS Group decreased their price objective on shares of Danaher from $309.00 to $305.00 and set a “buy” rating for the company in a research note on Wednesday, October 23rd. Royal Bank of Canada reduced their target price on shares of Danaher from $333.00 to $311.00 and set an “outperform” rating for the company in a report on Wednesday, October 23rd. Stifel Nicolaus upped their price target on shares of Danaher from $250.00 to $265.00 and gave the company a “hold” rating in a report on Wednesday, October 23rd. Finally, The Goldman Sachs Group lifted their price objective on Danaher from $225.00 to $250.00 and gave the company a “neutral” rating in a research note on Wednesday, July 24th. Six research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $287.16.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.